Isomorphic Labs, an AI-first drug design and development company, announced it has raised $600 million in its first external funding round. The funding round is led by Thrive Capital, with participation from GV, and follow-on capital from existing investor Alphabet.
Isomorphic Labs was launched with the ambition to leverage the power of AI to reimagine and accelerate drug discovery to bring much-needed treatments to millions of patients globally. And the company aims to apply its pioneering AI drug design engine to deliver biomedical breakthroughs and is advancing drug design programs across multiple therapeutic areas and drug modalities.
Since its founding, the company has developed a number of next-generation AI models that combine to form its unified AI drug design engine, which works across multiple therapeutic areas and drug modalities. One example of a breakthrough model is AlphaFold 3, developed and released in May 2024 by Isomorphic Labs together with Google DeepMind. It can accurately predict the structure and interactions of all of life’s molecules.
Utilizing these AI technologies, Isomorphic Labs has established a drug discovery portfolio consisting of partnered programs with pharmaceutical industry leaders Eli Lilly and Novartis and internal programs primarily focused on oncology and immunology. And Novartis and Isomorphic Labs recently expanded the scope of their original collaboration just over a year after initiating the relationship.
The funding will accelerate Isomorphic Labs’ frontier AI research and development, rapidly advancing the company’s next-generation AI drug design engine. As part of its next phase of growth, Isomorphic Labs will consequently expand its team of world-class talent.
KEY QUOTES:
“We’re excited to bring together a top-tier investor group with deep AI and life sciences expertise as we aim to transform this industry through an interdisciplinary approach. This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI.”
- Isomorphic Labs founder and CEO, Sir Demis Hassabis
“At Thrive, we aim to invest in category-defining companies with singular conviction, and that has led us to Isomorphic Labs. We believe Isomorphic has earned a rare position to define a new age of drug discovery and design, and we are deeply inspired by their mission and the extraordinary progress they have made to date.”
- Joshua Kushner, Founder and CEO of Thrive Capital
“AI and machine learning have long held the promise of transforming drug discovery, yet few companies over the past decade have unlocked their full potential. After witnessing the extraordinary pace of innovation at Isomorphic Labs, we believe their pioneering approach will redefine AI-powered drug discovery. With Sir Demis Hassabis at the helm, Isomorphic has assembled an exceptional team at the intersection of life sciences and technology. We’re proud to support them as they advance the development of new treatments for patients.”
- Dr. Krishna Yeshwant, Managing Partner at GV
